AST and ALT levels were significantly higher in subjects who developed fatty liver disease than in those with non-fatty liver disease (25), and these levels thus provide significant biomarkers for the effect of weight loss interventions among individuals with NAFLD (6). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.